What is Auristone?
Auristone operates at the intersection of advanced data analytics and molecular biology, specializing in epigenomic profiling to enhance drug and biomarker discovery. The company's flagship offering, EPI-Call, represents a significant advancement in second-generation Next Generation Sequencing (NGS) technology. Unlike traditional genomic tests, EPI-Call provides a comprehensive view of the tumor micro-environment, offering clinicians critical insights into patient responses to immunotherapy. By integrating DNA-seq with complex epigenomic data, Auristone provides a pragmatic, high-precision tool that assists physicians in tailoring treatment protocols, thereby improving patient outcomes in complex oncology cases.
How much funding has Auristone raised?
Auristone has raised a total of $5.4M across 1 funding round:
Angel/Seed
$5.4M
Angel/Seed (2024): $5.4M with participation from Genedant, Elev8.vc, and Seeds Capital
Key Investors in Auristone
Genedant
Genedant Capital specializes in providing reliable private and public market strategies, bespoke solutions, and long-term investment expertise aimed at fostering resilient portfolio growth.
Elev8.vc
Elev8.vc is a venture firm focused on deep tech and breakthrough scientific discoveries, partnering with founders to build global champions in healthcare and computing.
Seeds Capital
Seeds Capital is an investment firm that provides strategic backing to emerging companies, leveraging its industry expertise to support long-term operational success.
What's next for Auristone?
With the infusion of this latest capital, Auristone is poised to deepen its investment in R&D and expand the utility of its EPI-Call platform. The strategic roadmap focuses on strengthening its proprietary Asian epigenomic database, which serves as the backbone for its predictive analytics capabilities. As the company scales, it aims to forge deeper partnerships with pharmaceutical entities and healthcare providers to integrate its biomarker discovery tools into standard clinical workflows. This phase of growth is expected to solidify Auristone's role as a critical infrastructure provider in the global precision medicine ecosystem, driving innovation in how immunotherapy is prescribed and monitored.
See full Auristone company page
